Treatment with monoclonal antibodies has been shown to significantly reduce the risk of hospitalization and disease progression among high-risk patients with coronavirus disease 2019 (COVID-19). Pregnant individuals were excluded from the original trials. In this single-center retrospective cohort study, we evaluated whether monoclonal antibody treatment in pregnant individuals is associated with decreased risk of hospitalization. Outcomes of patients who received the treatment were compared with those who were eligible but did not receive the treatment. Analyses were stratified by vaccination status. Unvaccinated pregnant patients with mild or moderate COVID-19 who received outpatient monoclonal antibodies were less likely to be admitted to the hospital (4.2% vs 15.7%, odds ratio 0.24, 95% CI 0.07-0.74), whereas among vaccinated patients, the treatment was not associated with a lower rate of hospitalization (2.3% vs 0%, P=.99).

中文翻译：

---

2019 年轻度或中度冠状病毒病 (COVID-19) 孕妇门诊使用单克隆抗体。

单克隆抗体治疗已被证明可显着降低 2019 年冠状病毒病 (COVID-19) 高危患者的住院和疾病进展风险。怀孕的个体被排除在原始试验之外。在这项单中心回顾性队列研究中，我们评估了妊娠个体的单克隆抗体治疗是否与住院风险降低有关。将接受治疗的患者的结果与符合条件但未接受治疗的患者的结果进行比较。分析按疫苗接种状态分层。接受门诊单克隆抗体治疗的轻度或中度 COVID-19 未接种疫苗的妊娠患者住院的可能性较低（4.2% 对 15.7%，优势比 0.24，95% CI 0.07-0.74），而在接种疫苗的患者中，